Abhisheak Sharma

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7445734/publications.pdf

Version: 2024-02-01

257101 253896 1,999 67 24 43 citations g-index h-index papers 69 69 69 2582 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	The Lack of Contribution of 7-Hydroxymitragynine to the Antinociceptive Effects of Mitragynine in Mice: A Pharmacokinetic and Pharmacodynamic Study. Drug Metabolism and Disposition, 2022, 50, 158-167.	1.7	11
2	Characterization of Different Forms of Kava (Piper methysticum) Products by UPLC-MS/MS. Planta Medica, 2022, 88, 1348-1359.	0.7	5
3	UPLC-MS/MS method for the quantification of MCI-77, a novel sigma-1 receptor ligand, and its application to pharmacokinetic studies. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2022, 1196, 123187.	1.2	0
4	Clinical pharmacokinetics of kavalactones after oral dosing of standardized kava extract in healthy volunteers. Journal of Ethnopharmacology, 2022, 297, 115514.	2.0	4
5	Assessing the therapeutic potential and toxicity of <i>Mitragyna speciosa</i> in opioid use disorder. Expert Opinion on Drug Metabolism and Toxicology, 2021, 17, 255-257.	1.5	23
6	Preclinical pharmacokinetic study of speciociliatine, a kratom alkaloid, in rats using an UPLC-MS/MS method. Journal of Pharmaceutical and Biomedical Analysis, 2021, 194, 113778.	1.4	10
7	Exploring the Chemistry of Alkaloids from Malaysian <i>Mitragyna speciosa</i> (Kratom) and the Role of Oxindoles on Human Opioid Receptors. Journal of Natural Products, 2021, 84, 1034-1043.	1.5	45
8	Pharmacokinetics of Eleven Kratom Alkaloids Following an Oral Dose of Either Traditional or Commercial Kratom Products in Rats. Journal of Natural Products, 2021, 84, 1104-1112.	1.5	29
9	Oral Pharmacokinetics in Beagle Dogs of the Mitragynine Metabolite, 7-Hydroxymitragynine. European Journal of Drug Metabolism and Pharmacokinetics, 2021, 46, 459-463.	0.6	3
10	Pharmacokinetic and Biochemical Profiling of Sodium Dichloroacetate in Pregnant Ewes and Fetuses. Drug Metabolism and Disposition, 2021, 49, 451-458.	1.7	2
11	Acute morphine blocks spinal respiratory motor plasticity via longâ€latency mechanisms that require tollâ€like receptor 4 signalling. Journal of Physiology, 2021, 599, 3771-3797.	1.3	3
12	Activity of <i>Mitragyna speciosa</i> ("Kratomâ€) Alkaloids at Serotonin Receptors. Journal of Medicinal Chemistry, 2021, 64, 13510-13523.	2.9	30
13	Highly Specific Sigma Receptor Ligands Exhibit Anti-Viral Properties in SARS-CoV-2 Infected Cells. Pathogens, 2021, 10, 1514.	1.2	12
14	Exploration of cytochrome P450 inhibition mediated drug-drug interaction potential of kratom alkaloids. Toxicology Letters, 2020, 319, 148-154.	0.4	36
15	Patterns and reasons for kratom (Mitragyna speciosa) use among current and former opioid poly-drug users. Journal of Ethnopharmacology, 2020, 249, 112462.	2.0	61
16	Bioanalytical method development and validation of corynantheidine, a kratom alkaloid, using UPLC-MS/MS, and its application to preclinical pharmacokinetic studies. Journal of Pharmaceutical and Biomedical Analysis, 2020, 180, 113019.	1.4	14
17	Investigation of the Adrenergic and Opioid Binding Affinities, Metabolic Stability, Plasma Protein Binding Properties, and Functional Effects of Selected Indole-Based Kratom Alkaloids. Journal of Medicinal Chemistry, 2020, 63, 433-439.	2.9	92
18	Lyophilized Kratom Tea as a Therapeutic Option for Opioid Dependence. Drug and Alcohol Dependence, 2020, 216, 108310.	1.6	40

#	Article	IF	CITATIONS
19	Preliminary examination of mitragynine and $\hat{a}\in 7$ -hydroxymitragynine synthesis in response to production environment and postharvest techniques of <i>Mitragyna speciosa</i> . Acta Horticulturae, 2020, , 89-96.	0.1	3
20	Pharmacokinetics and Safety of Mitragynine in Beagle Dogs. Planta Medica, 2020, 86, 1278-1285.	0.7	19
21	Discovery of a Highly Selective Sigma-2 Receptor Ligand, 1-(4-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)butyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one (CM398), with Drug-Like Properties and Antinociceptive Effects In Vivo. AAPS Journal, 2020, 22, 94.	2.2	33
22	Metabolism of a Kratom Alkaloid Metabolite in Human Plasma Increases Its Opioid Potency and Efficacy. ACS Pharmacology and Translational Science, 2020, 3, 1063-1068.	2.5	36
23	Adolescent nicotine and tobacco smoke exposure enhances nicotine self-administration in female rats. Neuropharmacology, 2020, 176, 108243.	2.0	14
24	Bioanalytical method development and pharmacokinetics of MCI-92, a sigma-1 receptor ligand. Journal of Pharmaceutical and Biomedical Analysis, 2020, 191, 113610.	1.4	5
25	Evaluation of the rewarding effects of mitragynine and 7â€hydroxymitragynine in an intracranial self-stimulation procedure in male and female rats. Drug and Alcohol Dependence, 2020, 215, 108235.	1.6	19
26	Effects of Nutrient Fertility on Growth and Alkaloidal Content in Mitragyna speciosa (Kratom). Frontiers in Plant Science, 2020, 11, 597696.	1.7	17
27	Regulatory sampling of industrial hemp plant samples (Cannabis sativa L.) using UPLC-MS/MS method for detection and quantification of twelve cannabinoids. Journal of Cannabis Research, 2020, 2, 42.	1.5	8
28	Exploring 1-adamantanamine as an alternative amine moiety for metabolically labile azepane ring in newly synthesized benzo[d]thiazol-2(3H)one if receptor ligands. Medicinal Chemistry Research, 2020, 29, 1697-1706.	1.1	6
29	Potential Contribution of 7â€Hydroxymitragynine, a Metabolite of the Primary Kratom (Mitragyna) Tj ETQq1 1-1.	1 0.784314 rg 0.2	_
30	Potential biochemical mechanisms of the dual sigmaâ€1 and dopamine transporter ligand CM699. FASEB Journal, 2020, 34, 1-1.	0.2	0
31	Simultaneous quantification of ten key Kratom alkaloids in <i>Mitragyna speciosa</i> leaf extracts and commercial products by ultraâ€performance liquid chromatographyâ^'tandem mass spectrometry. Drug Testing and Analysis, 2019, 11, 1162-1171.	1.6	62
32	Bioanalytical method development and validation of MES207, a neuropeptide FF receptor antagonist, and its application in preclinical pharmacokinetics. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2019, 1134-1135, 121875.	1.2	0
33	A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity. Nature Medicine, 2019, 25, 1938-1947.	15.2	348
34	Improved chemotherapy against breast cancer through immunotherapeutic activity of fucoidan decorated electrostatically assembled nanoparticles bearing doxorubicin. International Journal of Biological Macromolecules, 2019, 122, 1100-1114.	3.6	51
35	Metabolite profiling and identification of enzymes responsible for the metabolism of mitragynine, the major alkaloid of <i>Mitragyna speciosa</i> (kratom). Xenobiotica, 2019, 49, 1279-1288.	0.5	70
36	Comparative Pharmacokinetics of Mitragynine after Oral Administration of Mitragyna speciosa (Kratom) Leaf Extracts in Rats. Planta Medica, 2019, 85, 340-346.	0.7	36

#	Article	IF	CITATIONS
37	A novel proteotoxic combination therapy for EGFR+ and HER2+ cancers. Oncogene, 2019, 38, 4264-4282.	2.6	8
38	A pharmacokinetic comparison of homodimer ARB-92 and heterodimer ARB-89: novel, potent antimalarial candidates derived from 7β-hydroxyartemisinin. Journal of Pharmaceutical Investigation, 2018, 48, 585-593.	2.7	6
39	A stable isotope dilution tandem mass spectrometry method of major kavalactones and its applications. PLoS ONE, 2018, 13, e0197940.	1.1	15
40	Ameliorative potential of ferulic acid in vincristine-induced painful neuropathy in rats: An evidence of behavioral and biochemical examination. Nutritional Neuroscience, 2017, 20, 60-70.	1.5	52
41	Doxorubicin Hydrochloride Loaded Zymosan-Polyethylenimine Biopolymeric Nanoparticles for Dual â€~Chemoimmunotherapeutic' Intervention in Breast Cancer. Pharmaceutical Research, 2017, 34, 1857-1871.	1.7	13
42	Simultaneous LC–MS-MS Determination of Lopinavir and Rifabutin in Human Plasma. Journal of Chromatographic Science, 2017, 55, 617-624.	0.7	4
43	Quantification of highly selective sigma†receptor antagonist CM304 using liquid chromatography tandem mass spectrometry and its application to a preâ€clinical pharmacokinetic study. Drug Testing and Analysis, 2017, 9, 1236-1242.	1.6	10
44	Model based population PK-PD analysis of furosemide for BP lowering effect: A comparative study in primary and secondary hypertension. European Journal of Pharmaceutical Sciences, 2017, 109, 253-261.	1.9	0
45	Effect of arteether and pyrimethamine coadministration on the pharmacokinetic and pharmacodynamic profile of ormeloxifene. Naunyn-Schmiedeberg's Archives of Pharmacology, 2017, 390, 971-976.	1.4	O
46	Preclinical pharmacokinetics and ADME characterization of a novel anticancer chalcone, cardamonin. Drug Testing and Analysis, 2017, 9, 1124-1136.	1.6	25
47	A combination of complexation and self-nanoemulsifying drug delivery system for enhancing oral bioavailability and anticancer efficacy of curcumin. Drug Development and Industrial Pharmacy, 2017, 43, 847-861.	0.9	62
48	Insights into the pharmacokinetic properties of antitubercular drugs. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 765-778.	1.5	3
49	PK–PD interaction study of angiotensin II antagonist, losartan, with selective estrogen receptor modulator, centchroman. International Journal of Pharmacokinetics, 2016, 1, 17-23.	0.5	1
50	Suspected Adulteration of Commercial Kratom Products with 7-Hydroxymitragynine. Journal of Medical Toxicology, 2016, 12, 341-349.	0.8	93
51	A mechanistic investigation of the bioavailability enhancing potential of lysergol, a novel bioenhancer, using curcumin. RSC Advances, 2016, 6, 58933-58942.	1.7	9
52	Identification of a diverse indole-2-carboxamides as a potent antileishmanial chemotypes. European Journal of Medicinal Chemistry, 2016, 110, 237-245.	2.6	19
53	Identification of gallic acid based glycoconjugates as a novel tubulin polymerization inhibitors. Organic and Biomolecular Chemistry, 2016, 14, 1338-1358.	1.5	25
54	Role of enterohepatic recirculation in drug disposition: cooperation and complications. Drug Metabolism Reviews, 2016, 48, 281-327.	1.5	45

#	Article	IF	CITATIONS
55	LC-coupled ESI MS for quantification of miltefosine in human and hamster plasma. Bioanalysis, 2016, 8, 533-545.	0.6	7
56	Identification of \hat{l}^2 -Amino alcohol grafted 1,4,5 trisubstituted 1,2,3-triazoles as potent antimalarial agents. European Journal of Medicinal Chemistry, 2016, 109, 187-198.	2.6	29
57	Rapid quantitative analysis of ormeloxifene and its active metabolite, 7-desmethyl ormeloxifene, in rat plasma using liquid chromatography-tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2015, 997, 7-15.	1.2	4
58	Gender-related pharmacokinetics and bioavailability of a novel anticancer chalcone, cardamonin, in rats determined by liquid chromatography tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2015, 986-987, 23-30.	1.2	14
59	Novel, potent, orally bioavailable and selective mycobacterial ATP synthase inhibitors that demonstrated activity against both replicating and non-replicating M. tuberculosis. Bioorganic and Medicinal Chemistry, 2015, 23, 742-752.	1.4	45
60	HPLC–MS-MS Method Development and Validation of Antileishmanial Agent, S010-0269, in Hamster Serum. Journal of Chromatographic Science, 2015, 53, 1542-1548.	0.7	3
61	Coadministration of HMG-CoA reductase inhibitors, atorvastatin and rosuvastatin, does not affect contraceptive efficacy of centchroman. European Journal of Contraception and Reproductive Health Care, 2015, 20, 231-235.	0.6	0
62	Preclinical Evaluation of DMA, a Bisbenzimidazole, as Radioprotector: Toxicity, Pharmacokinetics, and Biodistribution Studies in Balb/c Mice. Molecular Pharmacology, 2015, 88, 768-778.	1.0	9
63	Dried blood spots: Concepts, present status, and future perspectives in bioanalysis. Drug Testing and Analysis, 2014, 6, 399-414.	1.6	124
64	Novel pre-clinical methodologies for pharmacokinetic drug–drug interaction studies: spotlight on "humanized―animal models. Drug Metabolism Reviews, 2014, 46, 475-493.	1.5	28
65	Identification of Novel Phenyl Butenonyl C-Glycosides with Ureidyl and Sulfonamidyl Moieties as Antimalarial Agents. ACS Medicinal Chemistry Letters, 2014, 5, 878-883.	1.3	13
66	Discovery of a New Class of Natural Product-Inspired Quinazolinone Hybrid as Potent Antileishmanial agents. Journal of Medicinal Chemistry, 2013, 56, 4374-4392.	2.9	120
67	Synthesis and bioevaluation of novel 4-aminoquinoline-tetrazole derivatives as potent antimalarial agents. European Journal of Medicinal Chemistry, 2013, 66, 69-81.	2.6	61